Skip to Main Content

About Genentech, Inc.

"The few, the proud, the profitable" could be Genentech's motto. One of the world's oldest and most successful biotechs (in an industry full of money-losers), the firm has a number of blockbuster cancer therapies based on its antibody (protein) technologies. Its oncology portfolio contains Rituxan (non-Hodgkin's lymphoma), Avastin (colorectal and lung cancers), Herceptin (breast cancer), Tarceva (lung cancer), Xeloda (metastatic colorectal cancer), and Zelboraf (inoperable melanoma). Other marketed drugs include age-related macular degeneration treatment Lucentis, human growth hormone Nutropin, cystic fibrosis drug Pulmozyme, and asthma drug Xolair. Genentech is wholly owned by Swiss pharma powerhouse Roche.

Operations

Roche's control of Genentech places the larger drugmaker in the fast lane of biopharmaceuticals. Roche depends on Genentech's creative and successful research organization to keep its drug pipeline full of promising new biotech drugs, thus relieving stress from patent-expiration pressures in its existing product lineup.

Genentech's San Francisco office is now the primary administrative and marketing headquarters for Roche in the US and has taken over US sales efforts for Roche products including Tamiflu (influenza), Pegasys (hepatitis), CellCept (transplants), and Xeloda (colorectal cancer).

The company has some 1,200 researchers and scientists and 125 postdocs. It also has around 35 medicines on the market and nearly 20 more ADC's in its pipeline.

Geographic Reach

Genentech serves as the US headquarters for its parent, Roche. The company has offices three offices in California along with single offices in Oregon and Kentucky.

Sales and Marketing

Genentech's products are distributed through wholesalers including AmerisourceBergen, McKesson, and Cardinal Health. In international markets its products are primarily marketed through parent Roche's global sales force and distribution network.

Strategy

Instead of acquisitions, Genentech has traditionally relied on internal efforts (often with research partners) to develop and commercialize new drugs. More than half of its commercial product sales, as well as a majority of development projects, relate to oncology. The company's development-stage pharmaceuticals in clinical trials include personalized medicines for treating various cancers, including skin cancers and breast cancer, and such ailments as lupus, arthritis, asthma, diabetes, and Alzheimer's disease. Genentech has development partnerships with a number of firms including Seattle Genetics (cancers), NovImmune (autoimmune diseases), and Adimab (antibody studies). 

While its long-term success depends on its ability to develop novel compounds (especially as older drugs lose patent protection), Genentech is also seeking shorter-term success by boosting commercialization efforts for existing top sellers, including Avastin, Rituxan (known internationally as MabThera), and Lucentis. Part of the company's success comes from its efforts to expand the number of approved uses of its marketed drugs. 

Mergers and Acquisitions

In 2018 Genentech acquired Jecure Therapeutics, which specializes in non-alcoholic steatohepatitis (NASH) treatments, for an undisclosed amount. That deal will help Genentech with its inflammatory diseases work.

Company Background

Roche, which previously owned a majority stake in Genentech, made the company a wholly owned subsidiary in 2009 when it purchased the 44% of Genentech that it did not already own for about $47 billion. Through its 33% stake in Roche, Novartis is an indirect shareholder in Genentech. Novartis holds international licensing rights for Xolair and Lucentis (Genentech holds commercial rights in the US).

Since taking full ownership of Genentech (previously a majority-owned subsidiary) in 2009, Roche has cut expenses by combining the two companies' global manufacturing and supply networks and by integrating the research, marketing, and administrative operations in the US, while at the same time working to maintain Genentech's innovative identity and culture.

Genentech, Inc.

1 Dna Way
South San Francisco, CA 94080-4990
Phone: (650) 225-1000

Stats

Employer Type: Privately Owned
CEO: Bill Anderson
Chairman: Severin Schwan
EVP Genentech Research and Early Development: Michael D. Varney
Employees (This Location): 2,000
Employees (All Locations): 11,174